Cellectar Biosciences (CLRB) director granted 37,500 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cellectar Biosciences director Douglas J. Swirsky received a grant of stock options covering 37,500 shares of common stock at an exercise price of $2.70 per share. The option vests in full on July 7, 2027, subject to his continued service, and expires on July 7, 2036. This is a compensation grant, with no open-market share purchases or sales reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Swirsky Douglas J
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 37,500 | $0.00 | -- |
Holdings After Transaction:
Stock option (right to buy) — 37,500 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 37,500 options
Exercise price: $2.70 per share
Vesting date: July 7, 2027
+2 more
5 metrics
Option grant size
37,500 options
Stock option award to director Douglas J. Swirsky
Exercise price
$2.70 per share
Exercise price of granted stock options
Vesting date
July 7, 2027
Options vest in full on this date
Expiration date
July 7, 2036
Options expire on this date
Derivative holdings after grant
37,500 options
Total options held following this transaction
Key Terms
Stock option (right to buy), Grant, award, or other acquisition, Exercise price, Vesting, +1 more
5 terms
Stock option (right to buy) financial
"Security title is listed as "Stock option (right to buy)"."
Grant, award, or other acquisition financial
"Transaction code description states "Grant, award, or other acquisition"."
Exercise price financial
"The conversion or exercise price is reported as 2.7000 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Vesting financial
"The option shall vest in full on July 7, 2027, subject to service."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Expiration date financial
"The option’s expiration date is disclosed as July 7, 2036."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What insider transaction did Cellectar Biosciences (CLRB) report for Douglas J. Swirsky?
Cellectar Biosciences reported that director Douglas J. Swirsky received a grant of stock options for 37,500 shares. These options are a compensation award, not an open-market trade, and give him the right to buy common stock at a fixed exercise price.
How many Cellectar Biosciences (CLRB) stock options were granted to Douglas J. Swirsky?
Douglas J. Swirsky was granted stock options covering 37,500 shares of Cellectar Biosciences common stock. This entire amount is reflected as his derivative holdings following the transaction, indicating a single new option award reported in this filing.
What is the exercise price of Douglas J. Swirsky’s Cellectar (CLRB) stock options?
The stock options granted to Douglas J. Swirsky have an exercise price of $2.70 per share. This means he can buy Cellectar common stock at $2.70 if he exercises the options after they vest and before they expire.
When do Douglas J. Swirsky’s Cellectar Biosciences (CLRB) options vest and expire?
The option grant to Douglas J. Swirsky vests in full on July 7, 2027, subject to his continued service. The options carry an expiration date of July 7, 2036, defining the final date on which they can be exercised.
Does the Cellectar Biosciences (CLRB) Form 4 show any stock being bought or sold on the market?
The Form 4 reports only a grant of stock options to Douglas J. Swirsky coded as a grant or award acquisition. It does not disclose any open-market purchases or sales of Cellectar common stock by him in this transaction.